Dr. Sasine on Determining Outlook With CAR T-Cell Therapy in Hematologic Cancers

Video

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, University of California, Los Angeles, discusses how to determine if a patient will have a response to CAR T-cell therapy.

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, University of California, Los Angeles, discusses how to determine if a patient will have a response to CAR T-cell therapy.

Currently, it is difficult to determine who is going to benefit the most from CAR T-cell therapy, according to Sasine. However, researchers are getting closer to that because there are certain cytokine profiles now known, both before and after CAR T cells are given, that are associated with long-term, durable remissions, explains Sasine.

Lymphodepletion can also be a signal to determine response to CAR T cell therapy. This is something that can be modified within a physician's control, whereas other aspects are unmodifiable but can be helpful for predicting response.

Related Videos
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Abhishek Gupta, BS, the senior vice president of genetic medicines at Syneos Health
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Luke Roberts, MBBS, PhD, on Early Clinical Data on Congestive Heart Failure Gene Therapy
Lawrence R. Lustig, MD, the chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians
© 2024 MJH Life Sciences

All rights reserved.